Author

R. Filler

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 3 Organism:mouse· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Assay:ChIP-seq· 1 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

C. B. Wilen· 2 shared A. I. Ko· 1 shared A. McNamara· 1 shared A. Muller· 1 shared A. O. Kolawole· 1 shared A. Sanchez· 1 shared B. L. Menasche· 1 shared B. Menasche· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 19 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

C. B. Wilen

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Differences in syncytia formation by SARS-CoV-2 variants modify host chromatin accessibility and cellular senescence via TP53

J. D. Lee, B. L. Menasche, M. Mavrikaki, M. M. Uyemura, S. M. Hong, N. Kozlova, J. Wei, M. M. Alfajaro, R. Filler, A. Muller, T. Saxena, R. R. Posey, P. Cheung, T. Muranen, J. Heng, , F. J. Slack

This study shows that SARS-CoV-2 variants differ in syncytia formation, which affects host chromatin accessibility, cellular senescence, and inflammation via TP53.

bioRxiv · Aug 31, 2023Microbiology

Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2

Z. Fang, L. Peng, R. Filler, K. Suzuki, A. McNamara, Q. Lin, P. A. Renauer, L. Yang, B. Menasche, A. Sanchez, P. Ren, Q. Xiong, M. Strine, P. Clark, C. Lin, , S. Chen

This study evaluates an Omicron-specific mRNA vaccine, showing it elicits strong antibody responses and outperforms WT boosters against Omicron and Delta variants.

bioRxiv · Feb 14, 2022Immunology

CD300lf is the primary physiologic receptor of murine norovirus but not human norovirus

V. Graziano, F. C. Walker, E. A. Kennedy, J. Wei, K. Ettayebi, M. Simoes, R. Filler, E. Hassan, L. L. Hsieh, A. O. Kolawole, C. Wobus, L. C. Lindesmith, R. S. Baric, M. Estes, R. C. Orchard, , C. Wilen

This paper identifies CD300lf as the primary receptor for murine norovirus in vivo but shows it is not used by human norovirus.

PLOS Pathogens · Apr 6, 2020Peer-reviewedMicrobiology